CURRENT MEDICATIONS OVERVIEW,,
MEDICATION,GENE(S),PRESCRIBING CONSIDERATIONS BASED ON myDNA TEST
"Nortriptyline",CYP2D6,"Minor – result should be considered as may affect medicationresponse"
"Propranolol","CYP1A2CYP2D6","Minor – result should be considered as may affect medicationresponse"
"Sertraline",CYP2C19,"Minor – result should be considered as may affect medicationresponse"
"Codeine (componentof Acetaminophen-Caffeine-Codeine)","CYP2D6OPRM1",Usual prescribing considerations apply
MEDICATIONS THAT DO NOT HAVE PRESCRIBING CONSIDERATIONS BASED ON myDNA TEST,,
"trazadone, valaciclovir, prednisone, mycophenolate, acetaminophen (component of Acetaminophen-Caffeine-Codeine), caffeine (component of Acetaminophen-Caffeine-Codeine)",,
MEDICATIONS WITH MAJOR PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
Anticoagulants,Acenocoumarol,"VKORC1CYP2C9","Significantly increasedacenocoumarol sensitivity",DPWG
"",Warfarin,"VKORC1CYP2C9","Significantly increased warfarinsensitivity",FDA4
"Antidepressants -SSRIs",Citalopram,CYP2C19,Reduced / inadequate response,CPIC2
"",Escitalopram,CYP2C19,Reduced / inadequate response,CPIC2
"Antidepressants -tricyclicantidepressants",Amitriptyline,"CYP2D6CYP2C19",Reduced / inadequate response,CPIC1
"",Clomipramine,"CYP2D6CYP2C19",Reduced / inadequate response,CPIC1
"",Doxepin,"CYP2D6CYP2C19",Reduced / inadequate response,CPIC1
"",Imipramine,"CYP2D6CYP2C19",Reduced / inadequate response,CPIC1
Antiepileptics,Phenytoin,CYP2C9,Adverse effects,CPIC5
Antifungals - Azoles,Voriconazole,CYP2C19,Reduced / inadequate response,CPIC6
MEDICATIONS WITH MINOR PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
"ADHD -miscellaneous agents",Atomoxetine,CYP2D6,Adverse effects,-
"Angiotensin receptorblockers",Irbesartan,CYP2C9,"Increased therapeutic and/oradverse effects",-
Antiarrhythmics,Flecainide,CYP2D6,Adverse effects,DPWG7
"",Propafenone,CYP2D6,Adverse effects,DPWG7
"Antidepressants -other",Mirtazapine,"CYP2D6CYP1A2",Altered response,-
"",Moclobemide,CYP2C19,Reduced / inadequate response,-
"Antidepressants -serotoninnoradrenalinereuptake inhibitors",Duloxetine,"CYP2D6CYP1A2",Reduced / inadequate response,-
"",Venlafaxine,CYP2D6,Adverse effects,DPWG7
"Antidepressants -SSRIs",Paroxetine,CYP2D6,Adverse effects,CPIC2
"",Sertraline,CYP2C19,Reduced / inadequate response,CPIC2
"Antidepressants -tricyclicantidepressants",Desipramine,CYP2D6,Adverse effects,CPIC1
"",Nortriptyline,CYP2D6,Adverse effects,CPIC1
Antidiabetics,Gliclazide,"CYP2C9CYP2C19","Increased therapeutic and/oradverse effects",-
Glimepiride,CYP2C9,"Increased therapeutic and/oradverse effects",-,
Glyburide,CYP2C9,"Increased therapeutic and/oradverse effects",-,
MEDICATIONS WITH MINOR PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
Antiemetics,Ondansetron,CYP2D6,"Increased therapeutic and/oradverse effects",CPIC8
Antihistamines,Chlorpheniramine,CYP2D6,Adverse effects,-
"",Dexchlorpheniramine,CYP2D6,Adverse effects,-
Antiplatelet drugs,Clopidogrel,CYP2C19,Adverse effects,CPIC9
Antipsychotics,Aripiprazole,CYP2D6,Adverse effects,-
"",Brexpiprazole,CYP2D6,Adverse effects,-
"",Clozapine,CYP1A2,Reduced / inadequate response,-
"",Haloperidol,CYP2D6,Adverse effects,-
"",Olanzapine,CYP1A2,Reduced / inadequate response,-
"",Pimozide,CYP2D6,Adverse effects,
"",Risperidone,CYP2D6,Adverse effects,DPWG7
"",Zuclopenthixol,CYP2D6,Adverse effects,DPWG7
Antitussives,Dextromethorphan,CYP2D6,Altered response,-
Benzodiazepines,Clobazam,CYP2C19,Reduced / inadequate response,-
"",Diazepam,CYP2C19,Reduced / inadequate response,-
Beta blockers,Metoprolol,CYP2D6,Adverse effects,DPWG7
"",Propranolol,"CYP2D6CYP1A2",Altered response,-
Hypnotics,Melatonin,CYP1A2,Reduced / inadequate response,-
"Immunomodulatorsand antineoplastics",Tamoxifen,CYP2D6,Reduced / inadequate response,CPIC10
Miscellaneous,Cyclophosphamide,CYP2C19,"Increased therapeutic and/oradverse effects",-
"",Eliglustat,CYP2D6,Adverse effects,TGA11
"",Naltrexone,OPRM1,"Associated with reducedresponse to naltrexone",
"",Proguanil,CYP2C19,Altered response,-
Neurological drugs,Tetrabenazine,CYP2D6,Adverse effects,FDA12
NSAIDs,Celecoxib,CYP2C9,"Increased therapeutic and/oradverse effects",-
"",Flurbiprofen,CYP2C9,Adverse effects,-
"",Ibuprofen,CYP2C9,Adverse effects,-
"",Meloxicam,CYP2C9,Adverse effects,-
"",Piroxicam,CYP2C9,Adverse effects,-
Opioid Analgesics,Morphine,OPRM1,"Associated with increasedtherapeutic and/or adverseeffects to morphine",-
"Proton pumpinhibitors",Dexlansoprazole,CYP2C19,Reduced / inadequate response,-
Esomeprazole,CYP2C19,Reduced / inadequate response,-,
Lansoprazole,CYP2C19,Reduced / inadequate response,-,
Omeprazole,CYP2C19,Reduced / inadequate response,-,
Pantoprazole,CYP2C19,Reduced / inadequate response,-,
Rabeprazole,CYP2C19,Reduced / inadequate response,-,
MEDICATIONS WITH USUAL PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
"Angiotensin receptorblockers",Losartan,CYP2C9,"No altered effect predicted bygenotype",-
"Anticholinergics(genitourinary)",Darifenacin,CYP2D6,"No altered effect predicted bygenotype",-
MEDICATIONS WITH USUAL PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
"",Fesoterodine,CYP2D6,"No altered effect predicted bygenotype",-
"",Tolterodine,CYP2D6,"No altered effect predicted bygenotype",-
Anticholinesterases,Donepezil,CYP2D6,"No altered effect predicted bygenotype",-
"",Galantamine,CYP2D6,"No altered effect predicted bygenotype",-
"Antidepressants -other",Vortioxetine,CYP2D6,"No altered effect predicted bygenotype",-
"Antidepressants -SSRIs",Fluoxetine,"CYP2D6CYP2C9","No altered effect predicted bygenotype",-
"",Fluvoxamine,"CYP2D6CYP1A2","No altered effect predicted bygenotype",CPIC2
Antiemetics,Metoclopramide,CYP2D6,"No altered effect predicted bygenotype",-
Antihistamines,Promethazine,CYP2D6,Adverse effects,-
Antipsychotics,Chlorpromazine,CYP2D6,"No altered effect predicted bygenotype",-
"",Quetiapine,CYP3A4,"No altered effect predicted bygenotype",-
Beta blockers,Carvedilol,CYP2D6,"No altered effect predicted bygenotype",-
"",Nebivolol,CYP2D6,"No altered effect predicted bygenotype",-
Calcineurin inhibitors,Tacrolimus,CYP3A5,"No altered effect predicted bygenotype",CPIC13
"Glaucoma - ocularpreparations",Timolol,CYP2D6,"No altered effect predicted bygenotype",-
Miscellaneous,Atazanavir,CYP3A5,"No altered effect predicted bygenotype",-
NSAIDs,Diclofenac,CYP2C9,"No altered effect predicted bygenotype",-
"",Indomethacin,CYP2C9,"No altered effect predicted bygenotype",-
"",Mefenamic Acid,CYP2C9,"No altered effect predicted bygenotype",-
Opioid Analgesics,Codeine,"CYP2D6OPRM1","Associated with increasedsensitivity to codeine",CPIC3
"",Hydrocodone,CYP2D6,"No altered effect predicted bygenotype",
"",Oxycodone,CYP2D6,"No altered effect predicted bygenotype",DPWG7
"",Tramadol,CYP2D6,"No altered effect predicted bygenotype",DPWG7
Psychostimulants,Dextroamphetamine,CYP2D6,"No altered effect predicted bygenotype",-
"",Lisdexamfetamine,CYP2D6,"No altered effect predicted bygenotype",-
Statins,Atorvastatin,"SLCO1B1CYP3A4","No altered effect predicted bygenotype",-
Fluvastatin,"SLCO1B1CYP2C9","No altered effect predicted bygenotype",-,
Pravastatin,SLCO1B1,"No altered effect predicted bygenotype",-,
MEDICATIONS WITH USUAL PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
"",Rosuvastatin,SLCO1B1,"No altered effect predicted bygenotype",-
Simvastatin,"SLCO1B1CYP3A4","No altered effect predicted bygenotype",CPIC14,
